PBI-671 / Perceive Bio - LARVOL DELTA

Small molecule inhibitor of DLK and LZK protects retinal ganglion cells in a nonhuman primate model of glaucoma (ARVO 2025) - "Finally, a single derivative, PBI-671, was tested in a NHP model of glaucoma...Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Preclinical • Glaucoma • Ophthalmology

Perceive Pharma Attracts $15M Series A Financing to Advance Ophthalmic Neuroprotection (PRNewswire) - "Perceive Pharma, a pharmaceutical company pioneering novel small molecule therapeutics in ophthalmology, today announced the closing of a $15M Series A funding round...Perceive Pharma is focused on the neuroprotective pathways first elucidated in a genomic screening by co-founders Drs. Don Zack and Derek Welsbie, who further collaborated with a key industry partner to position Perceive Pharma with a library of neuroprotective drug candidates, including its lead therapeutic candidate, PBI-671. Series A proceeds will advance the development of first-in-class therapies to prevent vision loss in glaucoma, and additional undisclosed disease areas."

Financing • Glaucoma